Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$48.80
$46.43
$14.78
▼
$62.32
$3.59B0.341.59 million shs972,564 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$7.76
$11.33
$2.08
▼
$15.37
$3.59B0.8815.40 million shs11.67 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.18
$10.71
$6.62
▼
$15.35
$897.16M1.09650,412 shs732,221 shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$30.87
$22.75
$13.18
▼
$34.29
$3.51B1.072.89 million shs1.20 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%-1.27%+30.76%-18.02%+121.11%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.48%-43.02%+9.30%+214.17%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%+2.00%-1.08%-33.33%+12.09%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.00%+8.35%+62.22%+33.69%+7.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$48.80
$46.43
$14.78
▼
$62.32
$3.59B0.341.59 million shs972,564 shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$7.76
$11.33
$2.08
▼
$15.37
$3.59B0.8815.40 million shs11.67 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.18
$10.71
$6.62
▼
$15.35
$897.16M1.09650,412 shs732,221 shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$30.87
$22.75
$13.18
▼
$34.29
$3.51B1.072.89 million shs1.20 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%-1.27%+30.76%-18.02%+121.11%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%-3.48%-43.02%+9.30%+214.17%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%+2.00%-1.08%-33.33%+12.09%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.00%+8.35%+62.22%+33.69%+7.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.75
Moderate Buy$75.4454.60% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.71
Moderate Buy$13.8077.84% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.63
Moderate Buy$24.00161.44% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.83
Moderate Buy$41.0032.82% Upside

Current Analyst Ratings Breakdown

Latest MGTX, ELVN, IOVA, and VRDN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
DowngradeHold (C+) ➝ Hold (C)
11/11/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
UpgradeStrong Sell ➝ Hold
11/6/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Reiterated RatingBuy$78.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetOverweight$18.00 ➝ $19.00
11/6/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Boost Price TargetMarket Outperform$8.00 ➝ $12.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$38.00 ➝ $41.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$50.00 ➝ $54.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetBuy$39.00 ➝ $42.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOverweight$31.00 ➝ $34.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$41.00 ➝ $42.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetBuy$22.00 ➝ $40.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$7.74 per shareN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$263.50M13.62N/AN/A$1.76 per share4.41
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M11.02N/AN/A($0.07) per share-131.14
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$26.31M133.24N/AN/A$6.18 per share5.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.71N/AN/AN/AN/A-16.91%-16.52%N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.53N/AN/AN/A-58.20%-29.71%-23.55%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.8011.48N/AN/A19.46%85.23%24.12%N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$342.60M-$3.84N/AN/AN/A-1,620.79%-79.67%-44.72%N/A

Latest MGTX, ELVN, IOVA, and VRDN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.50-$0.53-$0.03-$0.53$6.95 million$4.81 million
11/5/2026Q3 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.4479-$0.36+$0.0879-$0.36N/AN/A
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.09-$0.05+$0.04-$0.05$115.98 million$121.47 million
11/4/2026Q3 2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$1.02-$0.81+$0.21-$0.81$4.72 million$25.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
45.95
45.95
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
5.20
4.67
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.57
4.62
4.62
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.50
14.46
14.46

Institutional Ownership

CompanyInstitutional Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
7.80%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
6573.60 million71.39 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975462.65 million426.57 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
39397.73 million90.50 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
252113.56 million110.83 millionOptionable

Recent News About These Companies

HC Wainwright Has Strong Forecast for VRDN FY2026 Earnings
Q4 Earnings Forecast for VRDN Issued By HC Wainwright
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $40.00
Analysts Offer Predictions for VRDN Q4 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$48.80 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$49.08 +0.28 (+0.56%)
As of 09:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$7.76 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$7.66 -0.10 (-1.29%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$9.18 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$9.08 -0.10 (-1.13%)
As of 09:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$30.87 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$31.14 +0.27 (+0.87%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.